In las conference NP mentioned that some cancer pa
Post# of 153820
(Total Views: 758)
Posted On: 04/25/2021 8:11:51 AM
In las conference NP mentioned that some cancer patients had ZERO CTCs after a year of treatment.
I have posted about this before as it is HUGE (if correct).
The conclusion of current research are clear:
1) CTC counts correlate with an improving prognosis. "Therefore, the diagnostic and predictive value of CTC and its role in the transformation of medical research have attracted more and more attention from medical science researchers, and are now popular topics in the field of cancer research."
2) A reduction of CTC counts will produce an increased OS (therapeutic benefit). "More than 90% of deaths in patients with malignant tumors are caused by distant metastasis and recurrence of tumor cells"
3) The elimination (if this is possible) of CTC counts means that Cancer is pretty much “stopped” on its tracks. Measurement of CAMLs is a complementary measurement
4) Measuring CTC’s is not an easy task. The CellSearch test is the only FDA-approved test for CTC assessment (metastatic breast, colorectal, or prostate cancer). Mayo clinic measures CTCs and maintains that this result provides a strong, independent predictor of survival.
There are other companies around offering CTC counts. Dr. Patterson has a counter (Genesis System) and claims identifying that a cell that predicts metastasis. He is working on sequencing CTC’s to compare with cells from original tumor for therapeutic purposes. He is targeting CCR5 (as we know) and says that: "by targeting CCR5, there is the potential not only treat the primary tumor but also to prevent metastasis because the cells that are being targeted are the ones contributing to the metastasis." We are using CreativMicrotech.
I am attaching below some articles related to CTCs (many more around). Some have been contributed by posters here.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493060/
https://www.ncbi.nlm.nih.gov/pubmed/30244877
www.sciencedirect.com/science/article/abs/pii/S1040842818305109?via%3Dihub
https://www.targetedonc.com/news/study-of-sm8...tic-cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505632/
https://www.onclive.com/conference-coverage/m...whats-next
https://jcmtjournal.com/article/view/1172
http://www.creatvmicrotech.com/ctc.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912467/
https://www.medpagetoday.com/meetingcoverage/...lsmm/87147
So, I hope we all understand the importance of last Proactive conference: NP said that we had several patients with zero CTC counts after an extended period (a year) on LL.
Now, let's assume there are SOME patients with REDUCED counts.
This is HUGE. Honestly I don't want to think we will cure cancer I would like to think we will be an important therapeutic on its fight.
I have posted about this before as it is HUGE (if correct).
The conclusion of current research are clear:
1) CTC counts correlate with an improving prognosis. "Therefore, the diagnostic and predictive value of CTC and its role in the transformation of medical research have attracted more and more attention from medical science researchers, and are now popular topics in the field of cancer research."
2) A reduction of CTC counts will produce an increased OS (therapeutic benefit). "More than 90% of deaths in patients with malignant tumors are caused by distant metastasis and recurrence of tumor cells"
3) The elimination (if this is possible) of CTC counts means that Cancer is pretty much “stopped” on its tracks. Measurement of CAMLs is a complementary measurement
4) Measuring CTC’s is not an easy task. The CellSearch test is the only FDA-approved test for CTC assessment (metastatic breast, colorectal, or prostate cancer). Mayo clinic measures CTCs and maintains that this result provides a strong, independent predictor of survival.
There are other companies around offering CTC counts. Dr. Patterson has a counter (Genesis System) and claims identifying that a cell that predicts metastasis. He is working on sequencing CTC’s to compare with cells from original tumor for therapeutic purposes. He is targeting CCR5 (as we know) and says that: "by targeting CCR5, there is the potential not only treat the primary tumor but also to prevent metastasis because the cells that are being targeted are the ones contributing to the metastasis." We are using CreativMicrotech.
I am attaching below some articles related to CTCs (many more around). Some have been contributed by posters here.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5493060/
https://www.ncbi.nlm.nih.gov/pubmed/30244877
www.sciencedirect.com/science/article/abs/pii/S1040842818305109?via%3Dihub
https://www.targetedonc.com/news/study-of-sm8...tic-cancer
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6505632/
https://www.onclive.com/conference-coverage/m...whats-next
https://jcmtjournal.com/article/view/1172
http://www.creatvmicrotech.com/ctc.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6912467/
https://www.medpagetoday.com/meetingcoverage/...lsmm/87147
So, I hope we all understand the importance of last Proactive conference: NP said that we had several patients with zero CTC counts after an extended period (a year) on LL.
Now, let's assume there are SOME patients with REDUCED counts.
This is HUGE. Honestly I don't want to think we will cure cancer I would like to think we will be an important therapeutic on its fight.
(19)
(0)